3 Rituximab Therapy in Children with Chronic Refractory Immune Cytopenia: Long Term Efficacy and Immune Analysis.
نویسندگان
چکیده
منابع مشابه
Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases
OBJECTIVE This paper prospectively evaluates the long-term follow-up [mean ± standard deviation (SD) duration: 89.7±19.4 months] data of 15 patients (13 females and 2 males) with refractory symptomatic immune thrombocytopenia (ITP) treated with rituximab. MATERIALS AND METHODS Rituximab was administered at 375 mg/m2 weekly for a total of 4 doses. Complete response (CR) was defined as a platel...
متن کاملLong-term cost-efficacy of rituximab in immune thrombocytopenic purpura.
Correspondence Long-term cost-efficacy of rituximab in immune thrombocytopenic purpura Sir, Prior to 1981, the only effective treatments for increasing platelet count in immune thrombo-cytopenic purpura (ITP) were corticosteroids and splenectomy. More recently, intravenous immuno-globulin (IVIg) and Rh immunoglobulin (IV RhIg) have demonstrated efficacy. Other treatments, including danazol, aza...
متن کاملCombination therapy of rituximab and corticosteroids for patients with refractory chronic immune thrombocytopenic purpura: report of two cases
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder, for which rituximab has been proven to be an effective treatment. The response rate was reported to be approximately 60% in refractory ITP patients. However, the response time is slower than expected, and the mechanism of action of rituximab in ITP is still unclear. Thus, sometimes, the use of a combination therapy with rituximab ...
متن کاملEvaluation of the efficacy and safety of rituximab in patients with refractory pemphigus vulgaris
Background: Recently, rituximab has been successfully used for the treatment of pemphigus family, the main subtype of which is pemphigus vulgaris (PV). The aim of this study was to determine the efficacy and safety of rituximab in refractory PV. Methods: In an observational study extending from November 2014 to February 2016, 30 patients with refractory PV were treated with rituximab. Response ...
متن کاملLong-Term Use of the Thrombopoietin-Mimetic Romiplostim in Children With Severe Chronic Immune Thrombocytopenia (ITP)
BACKGROUND Treatment of chronic severe pediatric ITP is not well studied. In a phase 1/2 12-16-week study, 15/17 romiplostim-treated patients achieved platelet counts ≥50 × 109 /L, and romiplostim treatment was well tolerated. In a subsequent open-label extension (≤109 weeks), 20/22 patients received romiplostim; all achieved platelet counts >50 × 109 /L. Twelve patients continued in a second e...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Research
سال: 2005
ISSN: 0031-3998,1530-0447
DOI: 10.1203/00006450-200510000-00033